Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Invivo Partners is a venture capital firm founded in 2012 and based in Barcelona, Spain. The firm specializes in early-stage investments in biotechnology and companies at the intersection of artificial intelligence (AI) and deep technology. Managed by a team of experienced professionals, including Luis Pareras, Albert Ferrer, and Laura Rodríguez, Invivo Partners has built a portfolio of 17 companies and achieved 4 successful exits. The firm manages a fund size of €100 million, targeting impactful investments in the health sector.
Since its inception, Invivo Partners has focused on leveraging a combination of scientific, technical, and financial expertise to support its portfolio companies. The firm is dedicated to fostering growth in the health sector through strategic investments that address significant challenges. Their geographical focus is primarily on European companies, with a notable emphasis on opportunities in Spain.
Invivo Partners primarily invests in the biotechnology sector, targeting companies that develop innovative drugs, particularly in advanced therapies and synthetic biology. The firm also focuses on AI-driven companies that address real-world problems, with a significant emphasis on healthcare solutions, which constitutes over 50% of their investment focus. Initial investments typically range from €2-4 million, with follow-on investments reaching up to €10 million per company after meeting specific milestones.
The firm targets pre-seed, seed, and Series A stages, particularly for companies that are 1-2 years away from first-in-human trials. Invivo Partners seeks impactful projects with strong proof of concept and robust intellectual property protection. Their investment strategy emphasizes the importance of scientific validation and market readiness, ensuring that their portfolio companies are well-positioned for success in the competitive biotech landscape.
Invivo Partners has invested in a diverse range of companies within the biotechnology and healthcare sectors. Notable portfolio companies include:
Luis Pareras: Founder and Managing Partner with extensive experience in venture capital and biotechnology investments.
Albert Ferrer: Founder Partner, specializing in early-stage investments and strategic guidance for portfolio companies.
Laura Rodríguez: Partner with a focus on operational support and investment analysis.
Begoña Aguirre: Executive Assistant and Office Manager, ensuring smooth operations within the firm.
Oscar Ferrer: Investment Analyst, involved in evaluating potential investments and supporting portfolio companies.
Michael Tadros: CEO of Telomere Therapeutics, bringing industry expertise to the team.
Claudio Santos: CEO of Gyala Therapeutics, contributing insights from the biotech sector.
Josep M. (Pep) Martorell: Advisor with extensive experience in academic and scientific management.
Cinta Díez: Investment Analyst, focusing on market research and investment opportunities.
Vicenç Gómez: Investment Analyst, supporting due diligence and portfolio management.
Borja Ruiz: Investment Analyst, involved in financial analysis and investment strategy.
Josep Maria Balaguer: Investment Analyst, contributing to investment evaluations and portfolio support.
To pitch to Invivo Partners, startups should submit their proposals through the firm's website at invivo.partners. The pitch deck should include a comprehensive overview of the business model, market analysis, team qualifications, and details about the technology. Invivo Partners prefers to receive warm introductions but will consider direct submissions as well.
Response times can vary, but founders can generally expect feedback within a few weeks. It is advisable to be concise and clear in the pitch, focusing on the most compelling aspects of the business.
Invivo Partners has been actively investing in innovative healthcare solutions, maintaining a portfolio of 17 companies and achieving 4 successful exits. The firm continues to focus on early-stage investments in biotechnology and AI-driven deep technology, particularly in healthcare.
Recent updates from Invivo Partners include their ongoing commitment to supporting portfolio companies through mentorship and operational guidance. The firm has also been sharing insights and developments related to their investments through their blog, although specific recent blog topics were not detailed.
What are Invivo Partners' investment criteria?
Invivo Partners focuses on early-stage investments in biotechnology and AI-driven deep technology, particularly in healthcare. They seek companies with strong proof of concept and robust intellectual property.
How can startups apply or pitch to Invivo Partners?
Startups can pitch to Invivo Partners through their website at invivo.partners. It is recommended to include a detailed business plan and information on the team, market potential, and technology.
What makes Invivo Partners different from other venture capital firms?
Invivo Partners combines scientific, technical, and financial expertise to support its portfolio companies, helping them navigate the complexities of drug development and market entry.
What is the geographical scope of Invivo Partners' investments?
The firm primarily invests in European-based companies, with a particular emphasis on opportunities in Spain.
What is the typical fund size and check size for investments?
Invivo Partners manages a fund size of €100 million, with initial investments ranging from €2-4 million and follow-on investments up to €10 million per company.
What is Invivo Partners' post-investment involvement like?
Invivo Partners adds value through mentorship and support in navigating drug development, leveraging their extensive network and expertise in the biotech sector.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.